Articles by bwarman

Professor Nick Lemoine recognised in the New Year Honours List

5th January 2022

Congratulations to Professor Nick Lemoine, Director of Barts Cancer Institute at Queen Mary University of London, who has received a CBE for services to clinical research, particularly during COVID-19.

Read more

Barts Cancer Institute at ASH 2021

17th December 2021

In December each year, the American Society of Hematology (ASH) hosts its Annual Meeting and Exposition – the premier event in malignant and non-malignant haematology. The event represents an invaluable opportunity for researchers at Barts Cancer Institute, Queen Mary University of London to highlight their blood cancer research on an international stage.

Read more

Investigating new strategies to target lung cancer

6th December 2021

Recent research from Barts Cancer Institute (BCI) at Queen Mary University of London has identified a novel therapeutic strategy to target lung cancer tumours that lack the gene LIMD1. We spoke with Professor Tyson V Sharp from BCI’s Centre for Cancer Cell & Molecular Biology, who led the study with Dr Sarah Martin, to find out more about the research and the significance of the findings.

Read more

Barts Cancer Institute hosts its first Robotic Surgery Symposium

3rd December 2021

On 4th November 2021, Barts Cancer Institute at Queen Mary University of London, in partnership with Barts Health NHS Trust, hosted its first Robotic Surgery Symposium, focused on the use of robotic systems for minimally invasive (or laparoscopic) surgery.

Read more

Prof Nick Lemoine interviewed on Channel 4 News about long COVID

29th November 2021

During the interview, Professor Lemoine highlighted that studies being undertaken across the country aim to elucidate the mechanisms involved in long COVID, and further studies are being set up to identify treatments that will be effective against the disease.

Read more

International collaboration set to investigate new treatment strategy for lymphoma

24th November 2021

An international collaboration involving researchers from Queen Mary University of London, Memorial Sloan Kettering Cancer Center, New York and Dana-Farber Cancer Institute, Boston has secured a €1M research grant from Dutch blood cancer charity, Lymph&Co, to investigate a new treatment target for lymphoma.

Read more

Search News